TABLE OF CONTENTS
1 INTRODUCTION 75
1.1 OBJECTIVES OF THE STUDY 75
1.2 MARKET DEFINITION 75
1.3 OVERVIEW OF THE GLOBAL LIPID PANEL TESTING MARKET 75
1.4 LIMITATIONS 77
1.5 MARKETS COVERED 78
2 MARKET SEGMENTATION 82
2.1 MARKETS COVERED 82
2.2 GEOGRAPHICAL SCOPE 83
2.3 YEARS CONSIDERED FOR THE STUDY 84
2.4 CURRENCY AND PRICING 84
2.5 DBMR TRIPOD DATA VALIDATION MODEL 85
2.6 MULTIVARIATE MODELLING 88
2.7 PRODUCTS & SERVICES LIFELINE CURVE 88
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 89
2.9 DBMR MARKET POSITION GRID 90
2.10 MARKET TESTING TYPE COVERAGE GRID 92
2.11 VENDOR SHARE ANALYSIS 93
2.12 SECONDARY SOURCES 94
2.13 ASSUMPTIONS 94
3 EXECUTIVE SUMMARY 95
4 PREMIUM INSIGHTS 98
4.1 PESTEL ANALYSIS 101
4.2 PORTERS FIVE FORCES 102
4.3 PATENT ANALYSIS 103
5 INDUSTRIAL INSIGHTS 106
5.1 KEY PRICING STRATEGY 106
6 GLOBAL LIPID PANEL TESTING MARKET, REGULATIONS 108
6.1 REGULATORY SCENARIO IN THE U.S 108
6.2 REGULATORY SCENARIO IN EUROPE 109
6.3 REGULATORY SCENARIO IN JAPAN 109
6.4 REGULATORY SCENARIO IN CHINA 109
7 MARKET OVERVIEW 111
7.1 DRIVERS 113
7.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 113
7.1.2 GROWING NUMBER OF CASES OF DYSLIPIDEMIA 114
7.1.3 RAPID CHANGES IN LIFESTYLE CHANGES LEAD TO LIPID DISORDERS 115
7.1.4 RISE IN PREFERENCE FOR HOMECARE TESTING IN LIPID PANEL TESTING 116
7.2 RESTRAINTS 117
7.2.1 STRICT GOVERNMENT REGULATIONS 117
7.2.2 HIGH COST ASSOCIATED WITH TESTING PANELS 118
7.3 OPPORTUNITIES 119
7.3.1 GROWTH IN TECHNOLOGICAL ADVANCEMENTS 119
7.3.2 RISE IN THE PREVALENCE OF OBESITY AMONG PEOPLE 119
7.3.3 INCREASING ADOPTION OF POINT-OF-CARE LIPID PANEL TESTING 120
7.4 CHALLENGES 121
7.4.1 LACK OF SKILLED & CERTIFIED PROFESSIONALS 121
7.4.2 LACK OF STANDARDIZATION OF LIPID PANEL TESTING 121
8 GLOBAL LIPID PANEL TESTING MARKET, BY PRODUCTS & SERVICES 123
8.1 OVERVIEW 124
8.2 SERVICES 127
8.2.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 128
8.2.2 TOTAL CHOLESTEROL TEST 128
8.2.3 HIGH DENSITY LIPOPROTEIN (HDL) TEST 128
8.2.4 TRIGLYCERIDES/ VLDL TEST 129
8.2.5 NON-HDL CHOLESTEROL TEST 129
8.2.6 OTHERS 130
8.3 KITS 130
8.3.1 STRIPS 131
8.3.1.1 THREE-ANALYTE TEST STRIPS 131
8.3.1.2 DUAL-ANALYTE TEST STRIPS 131
8.3.1.3 SINGLE-ANALYTE TEST STRIPS 131
8.3.2 LANCETS 131
8.3.3 CONTROLS 132
8.3.3.1 MULTI-CHEMISTRY CONTROLS 132
8.3.3.2 HDL CHOLESTEROL CONTROLS 132
8.3.3.3 OTHERS 132
8.3.4 CAPILLARY TUBES 132
8.4 DEVICES 133
8.4.1 BY MODALITY 133
8.4.1.1 STANDALONE 134
8.4.1.2 HANDHELD 134
8.4.1.3 PORTABLE 134
8.4.2 BY TYPE 134
8.4.2.1 LABORATORY BASED 134
8.4.2.2 POINT OF CARE BASED 134
9 GLOBAL LIPID PANEL TESTING MARKET, BY PRESCRIPTION MODE 135
9.1 OVERVIEW 136
9.2 PRESCRIPTION-BASED TESTING 139
9.3 OTC-BASED TESTING 140
10 GLOBAL LIPID PANEL TESTING MARKET, BY APPLICATION 141
10.1 OVERVIEW 142
10.2 HYPERLIPIDEMIA 145
10.2.1 TOTAL CHOLESTEROL TEST 146
10.2.2 TRIGLYCERIDES/ VLDL TEST 146
10.2.3 LOW DENSITY LIPOPROTEIN (LDL) TEST 146
10.2.4 HIGH DENSITY LIPOPROTEIN (HDL) TEST 146
10.2.5 NON-HDL CHOLESTEROL TEST 146
10.2.6 OTHERS 146
10.3 HYPERTRIGLYCERIDEMIA 147
10.3.1 TRIGLYCERIDES/ VLDL TEST 148
10.3.2 TOTAL CHOLESTEROL TEST 148
10.3.3 LOW DENSITY LIPOPROTEIN (LDL) TEST 148
10.3.4 HIGH DENSITY LIPOPROTEIN (HDL) TEST 148
10.3.5 NON-HDL CHOLESTEROL TEST 148
10.3.6 OTHERS 148
10.4 ATHEROSCLEROSIS 149
10.4.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 150
10.4.2 TOTAL CHOLESTEROL TEST 150
10.4.3 TRIGLYCERIDES/ VLDL TEST 150
10.4.4 HIGH DENSITY LIPOPROTEIN (HDL) TEST 150
10.4.5 NON-HDL CHOLESTEROL TEST 150
10.4.6 OTHERS 150
10.5 FAMILIAL HYPERCHOLESTEROLEMIA 151
10.5.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 152
10.5.2 TOTAL CHOLESTEROL TEST 152
10.5.3 HIGH DENSITY LIPOPROTEIN (HDL) TEST 152
10.5.4 TRIGLYCERIDES/ VLDL TEST 152
10.5.5 NON-HDL CHOLESTEROL TEST 152
10.5.6 OTHERS 152
10.6 HYPO LIPOPROTEINEMIA 153
10.6.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 154
10.6.2 HIGH DENSITY LIPOPROTEIN (HDL) TEST 154
10.6.3 TRIGLYCERIDES/ VLDL TEST 154
10.6.4 TOTAL CHOLESTEROL TEST 154
10.6.5 NON-HDL CHOLESTEROL TEST 154
10.6.6 OTHERS 154
10.7 TANGIER DISEASE 155
10.7.1 HIGH DENSITY LIPOPROTEIN (HDL) TEST 156
10.7.2 LOW DENSITY LIPOPROTEIN (LDL) TEST 156
10.7.3 TOTAL CHOLESTEROL TEST 156
10.7.4 TRIGLYCERIDES/ VLDL TEST 156
10.7.5 NON-HDL CHOLESTEROL TEST 156
10.7.6 OTHERS 156
10.8 OTHERS 157
11 GLOBAL LIPID PANEL TESTING MARKET, BY END USER 158
11.1 OVERVIEW 159
11.2 HOSPITAL 162
11.2.1 BY TYPE 162
11.2.1.1 PRIVATE 163
11.2.1.1.1 SERVICES 163
11.2.1.1.2 KITS 163
11.2.1.1.3 DEVICES 163
11.2.1.2 PUBLIC 163
11.2.1.2.1 SERVICES 164
11.2.1.2.2 KITS 164
11.2.1.2.3 DEVICES 164
11.2.2 BY TIER 164
11.2.2.1 TIER 1 164
11.2.2.1.1 SERVICES 165
11.2.2.1.2 KITS 165
11.2.2.1.3 DEVICES 165
11.2.2.2 TIER 2 165
11.2.2.2.1 SERVICES 165
11.2.2.2.2 KITS 165
11.2.2.2.3 DEVICES 165
11.2.2.3 TIER 3 165
11.2.2.3.1 SERVICES 166
11.2.2.3.2 KITS 166
11.2.2.3.3 DEVICES 166
11.3 DIAGNOSTIC CLINICS 166
11.3.1 SERVICES 167
11.3.2 KITS 167
11.3.3 DEVICES 167
11.4 SPECIALTY CLINICS & PHYSICIAN OFFICES 168
11.4.1 SERVICES 169
11.4.2 KITS 169
11.4.3 DEVICES 169
11.5 REFERENCE LABORATORIES 169
11.5.1 SERVICES 170
11.5.2 KITS 170
11.5.3 DEVICES 170
11.6 AMBULATORY SURGICAL CENTERS 170
11.6.1 SERVICES 171
11.6.2 KITS 171
11.6.3 DEVICES 171
11.7 PATHOLOGY LABORATORIES 172
11.7.1 SERVICES 173
11.7.2 KITS 173
11.7.3 DEVICES 173
11.8 ACADEMIC AND RESEARCH INSTITUTES 173
11.8.1 SERVICES 174
11.8.2 KITS 174
11.8.3 DEVICES 174
11.9 OTHERS 175
12 GLOBAL LIPID PANEL TESTING MARKET, BY DISTRIBUTION CHANNEL 176
12.1 OVERVIEW 177
12.2 DIRECT TENDER 180
12.3 RETAIL PHARMACY 180
12.3.1 HOSPITAL PHARMACIES 181
12.3.2 DRUG STORES 181
12.3.3 OTHERS 181
12.4 ONLINE SALES 182
12.5 OTHERS 183
13 GLOBAL LIPID PANEL TESTING MARKET, BY REGION 184
13.1 OVERVIEW 185
13.2 NORTH AMERICA 190
13.2.1 U.S. 207
13.2.2 CANADA 220
13.2.3 MEXICO 233
13.3 EUROPE 246
13.3.1 U.K. 260
13.3.2 GERMANY 270
13.3.3 FRANCE 280
13.3.4 RUSSIA 290
13.3.5 ITALY 300
13.3.6 SPAIN 310
13.3.7 TURKEY 320
13.3.8 NETHERLANDS 330
13.3.9 SWITZERLAND 340
13.3.10 REST OF EUROPE 350
13.4 ASIA-PACIFIC 351
13.4.1 CHINA 368
13.4.2 JAPAN 381
13.4.3 INDIA 394
13.4.4 AUSTRALIA 407
13.4.5 SOUTH KOREA 420
13.4.6 SINGAPORE 433
13.4.7 MALAYSIA 446
13.4.8 THAILAND 459
13.4.9 PHILIPPINES 472
13.4.10 INDONESIA 485
13.4.11 REST OF ASIA-PACIFC 498
13.5 SOUTH AMERICA 499
13.5.1 BRAZIL 516
13.5.2 ARGENTINA 528
13.5.3 REST OF SOUTH AMERICA 541
13.6 MIDDLE EAST AND AFRICA 542
13.6.1 SOUTH AFRICA 559
13.6.2 SAUDI ARABIA 572
13.6.3 EGYPT 585
13.6.4 UAE 598
13.6.5 ISRAEL 611
13.6.6 REST OF MIDDLE EAST AND AFRICA 624
14 GLOBAL LIPID PANEL TESTING MARKET, COMPANY LANDSCAPE 625
14.1 COMPANY SHARE ANALYSIS: GLOBAL 625
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 626
14.3 COMPANY SHARE ANALYSIS: EUROPE 627
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 628
15 SWOT ANALYSIS 629
16 GLOBAL LIPID PANEL TESTING MARKET, COMPANY PROFILE 630
16.1 QUEST DIAGNOSTICS INCORPORATED 630
16.1.1 COMPANY SNAPSHOT 630
16.1.2 REVENUE ANALYSIS 631
16.1.3 COMPANY SHARE ANALYSIS 631
16.1.4 PRODUCT PORTFOLIO 632
16.1.5 RECENT DEVELOPMENTS 632
16.2 EUROFINS SCIENTIFIC 633
16.2.1 COMPANY SNAPSHOT 633
16.2.2 REVENUE ANALYSIS 633
16.2.3 COMPANY SHARE ANALYSIS 634
16.2.4 PRODUCT PORTFOLIO 634
16.2.5 RECENT DEVELOPMENT 634
16.3 LABORATORY CORPORATION OF AMERICA HOLDINGS 635
16.3.1 COMPANY SNAPSHOT 635
16.3.2 REVENUE ANALYSIS 635
16.3.3 COMPANY SHARE ANALYSIS 636
16.3.4 PRODUCT PORTFOLIO 636
16.3.5 RECENT DEVELOPMENT 637

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.